Loading
companiesCompany
Beijing Konruns Pharmaceutical
Beijing Konruns Pharmaceutical is a Chinese developer in Beijing that sponsors 5 registered cancer trials of KC1036 and S-1.
Also called: Beijing Konruns Pharmaceutical Co., Ltd.
Overview
Beijing Konruns Pharmaceutical appears on ClinicalTrials.gov as the industry sponsor of 5 interventional cancer trials (phase 1/2, 2, 3), testing KC1036, S-1, Toripalimab in esophageal squamous cell carcinoma, esophageal squamous cell carcinoma (escc), digestive system tumors, thymic tumors. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Similar pages
- TreatmentKC1036
Shares A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma, A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer, A Study of KC1036 in Patients with Advanced Thymic Tumors, KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer.
- CompanyBeijing Gene Key Life Technology
Shares the tags china, registry-only.
- CompanyBeijing Mabworks Biotech
Shares the tags china, registry-only.
- CompanyBeijing Pearl Biotechnology Limited Liability Company
Shares the tags china, registry-only.
- CompanyBeijing Scitech-Mq Pharmaceuticals
Shares the tags china, registry-only.
- CompanyBeijing Tide Pharmaceutical
Shares the tags china, registry-only.
- CompanyBinhui Biopharmaceutical
Shares the tags china, registry-only.
- CompanyChengdu Zenitar Biomedical Technology
Shares the tags china, registry-only.
trials
A Study of KC1036 in Adolescents With Advanced Ewing SarcomaA Study of KC1036 in Patients with Advanced Thymic TumorsA Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal CancerKC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer